GeneDx Holdings (WGS) Cash & Equivalents (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Cash & Equivalents data on file, last reported at $93.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $93.9 million, down 5.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.9 million (down 5.8% YoY), and the FY2025 annual result was $105.0 million, up 23.22% from the prior year.
• Cash & Equivalents declined to $93.9 million in Q1 2026 per WGS's latest filing, from $105.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $315.0 million in Q1 2022 and troughed at $56.1 million in Q2 2024.
• A 5-year average of $130.1 million and a median of $99.7 million in 2023 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 973.92% in 2022 and fell as far as 69.06% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $123.9 million in 2022, then dropped by 19.57% to $99.7 million in 2023, then retreated by 14.52% to $85.2 million in 2024, then increased by 23.22% to $105.0 million in 2025, then fell by 10.55% to $93.9 million in 2026.
• Business Quant data shows WGS's Cash & Equivalents at $93.9 million in Q1 2026, $105.0 million in Q4 2025, and $96.0 million in Q3 2025.